Indaptus Therapeutics (INDP) News Today → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free INDP Stock Alerts $2.34 +0.03 (+1.30%) (As of 05/20/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 8, 2024 | investorplace.comINDP Stock Earnings: Indaptus Therapeutics Misses EPS for Q1 2024May 8, 2024 | globenewswire.comIndaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Indaptus Therapeutics Amidst Promising Clinical Advances and Potential Market ImpactApril 12, 2024 | investing.comIndaptus reveals immune-boosting cancer therapy dataApril 12, 2024 | markets.businessinsider.comBuy Rating for Indaptus Therapeutics: Promising Oncology Breakthrough with Decoy20 PlatformApril 11, 2024 | globenewswire.comIndaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual MeetingMarch 28, 2024 | msn.comArmaguard rebuffs $26m cash lifelineMarch 28, 2024 | finance.yahoo.comIndaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 25, 2024 | globenewswire.comIndaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual MeetingMarch 18, 2024 | finance.yahoo.comIndaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024March 13, 2024 | msn.comIndaptus Dives on Quarterly ResultsMarch 13, 2024 | benzinga.comIndaptus Therapeutics: Q4 Earnings InsightsMarch 13, 2024 | globenewswire.comIndaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateMarch 4, 2024 | markets.businessinsider.comIndaptus Reports Positive Decoy20 Results, To Advance To Multi-dosing; Stock Up In Pre-marketMarch 4, 2024 | globenewswire.comIndaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortMarch 4, 2024 | globenewswire.comIndaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortFebruary 25, 2024 | benzinga.comIndaptus Therapeutics Stock (NASDAQ:INDP) Insider TradesFebruary 15, 2024 | finance.yahoo.comIndaptus Therapeutics to Present at the 2024 BIO CEO & Investor ConferenceFebruary 8, 2024 | finance.yahoo.comIndaptus Therapeutics Expands Digital Presence with Launch of Social Media ChannelsJanuary 4, 2024 | finance.yahoo.comEuropean Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform TechnologyDecember 22, 2023 | finance.yahoo.comIndaptus Therapeutics, Inc. (INDP) stock forecast and price targetNovember 27, 2023 | msn.comIndaptus Therapeutics (INDP) Price Target Increased by 25.00% to 10.20November 7, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Ventyx Biosciences (VTYX) and Indaptus Therapeutics (INDP)November 6, 2023 | msn.comIndaptus Therapeutics GAAP EPS of -$0.47 beats by $0.05November 6, 2023 | finance.yahoo.comIndaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 6, 2023 | finance.yahoo.comIndaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 StudyNovember 4, 2023 | markets.businessinsider.comIndaptus Therapeutics: Promising Phase 1 Results and Optimistic Valuation Bolster Buy RatingOctober 31, 2023 | finance.yahoo.comIndaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy MeetingOctober 9, 2023 | finance.yahoo.comHere's Why We're Watching Indaptus Therapeutics' (NASDAQ:INDP) Cash Burn SituationSeptember 27, 2023 | finance.yahoo.comIndaptus Therapeutics to Present at the LD Micro Main Event XVISeptember 26, 2023 | finance.yahoo.comRegistration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023September 19, 2023 | finance.yahoo.comIndaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20September 6, 2023 | finance.yahoo.comIndaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 29, 2023 | finance.yahoo.comFavourable Signals For Indaptus Therapeutics: Numerous Insiders Acquired StockAugust 14, 2023 | finance.yahoo.comIndaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 11, 2023 | markets.businessinsider.comMaxim Group Remains a Buy on Indaptus Therapeutics (INDP)August 10, 2023 | finance.yahoo.comIndaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20August 7, 2023 | finance.yahoo.comIndaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical OfficerMay 31, 2023 | finance.yahoo.comIndaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023May 31, 2023 | finance.yahoo.comIndaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023May 9, 2023 | finance.yahoo.comFollowing Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy PlatformMay 4, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Indaptus TherapeuticsMay 4, 2023 | msn.comHC Wainwright & Co. Reiterates Indaptus Therapeutics (INDP) Buy RecommendationMay 2, 2023 | finance.yahoo.comWe Think Indaptus Therapeutics (NASDAQ:INDP) Needs To Drive Business Growth CarefullyMay 1, 2023 | benzinga.comIndaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies SummitMay 1, 2023 | finance.yahoo.comIndaptus Therapeutics’ Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies SummitApril 20, 2023 | finance.yahoo.comIndaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023April 19, 2023 | msn.comIndaptus Therapeutics Says Antitumor Platform Demonstrates Preclinical Efficacy Across Cancer IndicationsApril 19, 2023 | finance.yahoo.comIndaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023April 19, 2023 | finance.yahoo.comUPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023 Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address Must-See: Elon’s New Invention is Absolutely Insane (Ad)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone. Click here for the full story… INDP Media Mentions By Week INDP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INDP News Sentiment▼0.000.42▲Average Medical News Sentiment INDP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INDP Articles This Week▼00▲INDP Articles Average Week Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SLGL News AYTU News GLTO News COCP News VBIV News GLYC News KALA News NRBO News BIVI News NERV News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INDP) was last updated on 5/20/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsNext President (Not Trump. Not Biden.)The Freeport Society**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock Digest Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
